Breast Fibroadenoma
Conditions
Keywords
HIFU
Brief summary
This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.
Detailed description
Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.
Interventions
DEVICEECHOPULSE
HIFU Under ultrasound guidance
Sponsors
Theraclion
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma. 2. Diagnosis of fibroadenoma must be based on: 1. Clinical examination 2. Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if biopsy indicates fibroadenoma with concordance. 3. Histologic confirmation by core needle biopsy. 3. Patient is a candidate for the surgery. 4. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed. 5. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed. 6. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma. 7. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure). 8. Fibroadenoma is palpable. 9. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days 10. Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days 11. Patient has signed a written informed consent.
Exclusion criteria
1. Patient is pregnant or nursing. 2. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women \> 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram. 3. Patient with history of breast cancer or history of laser or radiation therapy to the target breast. 4. Patient with breast implants in the target breast. 5. Patient with a breast cyst within the fibroadenoma to be treated. 6. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. 7. Patient participating in another clinical trial involving an investigational drug, device or biologic.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain level assessment | 12 Months | visual analog scale |
| Anxiety level assessment | 12 Months | visual analog scale |
| Volume assessment | 12 Months | Ultrasound measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The short (6-item) version of the State-Trait Anxiety Inventory (STAI) | inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months | — |
| Palpability of the breast fibroadenoma | inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months | Physician clinical examination |
| Freedom from additional procedures for fibroadenoma of the breast | Day 2/3, Day 7, 6 months, 12 months | Physician assessment concerning the need of additional procedures |
| Patient satisfaction | Month 6 and Months 12 | Self assessment satisfaction questionnaire |
| Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial. | Day 0, Day 2/3, Day 7, 6 months, 12 months | Assessment and capture of adverse events |
Countries
United States
Contacts
STUDY_DIRECTORMichel NUTA, MD
Theraclion
Outcome results
None listed